全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

High-Amylose Sodium Carboxymethyl Starch Matrices: Development and Characterization of Tramadol Hydrochloride Sustained-Release Tablets for Oral Administration

DOI: 10.1155/2014/391523

Full-Text   Cite this paper   Add to My Lib

Abstract:

Substituted amylose (SA) polymers were produced from high-amylose corn starch by etherification of its hydroxyl groups with chloroacetate. Amorphous high-amylose sodium carboxymethyl starch (HASCA), the resulting SA polymer, was spray-dried to obtain an excipient (SD HASCA) with optimal binding and sustained-release (SR) properties. Tablets containing different percentages of SD HASCA and tramadol hydrochloride were produced by direct compression and evaluated for dissolution. Once-daily and twice-daily SD HASCA tablets containing two common dosages of tramadol hydrochloride (100?mg and 200?mg), a freely water-soluble drug, were successfully developed. These SR formulations presented high crushing forces, which facilitate further tablet processing and handling. When exposed to both a pH gradient simulating the pH variations through the gastrointestinal tract and a 40% ethanol medium, a very rigid gel formed progressively at the surface of the tablets providing controlled drug-release properties. These properties indicated that SD HASCA was a promising and robust excipient for oral, sustained drug-release, which may possibly minimize the likelihood of dose dumping and consequent adverse effects, even in the case of coadministration with alcohol. 1. Introduction Starch is a naturally occurring and a biodegradable polymer that is metabolized by the human body. Besides being nontoxic, starch is an abundant, cost-effective, and renewable material [1]. Due to these advantages, starches and modified starches have been widely and safely used in the food industry as thickeners, enhancers, of organoleptic properties, or texture modifiers and in the pharmaceutical industry as fillers, binders, disintegrants [2], and, more recently, as hydrophilic excipients for controlled drug-release. Numerous starch-modification methods, such as chemical [3], physical (i.e., gelatinization) [4], enzymatic [5], or a combination thereof, have been employed to produce new starch products with specific properties. Starch is a good candidate for chemical reaction or transformation because it is composed of amylose and amylopectin, two glucose polymers presenting three hydroxyl groups accessible as chemically active functional entities. Some of the modifications commonly employed to prepare starch derivatives are carboxymethylation, ethoxylation, and oxidation [6]. Substituted amylose (SA) has been introduced as a promising pharmaceutical excipient for sustained drug-release. SA matrix tablets have been prepared by direct compression, which is the easiest way to manufacture an oral

References

[1]  J. Kost and S. Shefer, “Chemically-modified polysaccharides for enzymatically-controlled oral drug delivery,” Biomaterials, vol. 11, no. 9, pp. 695–698, 1990.
[2]  C. G. Biliaderis, “The structure and interactions of starch with food constituents,” Canadian Journal of Physiology and Pharmacology, vol. 69, no. 1, pp. 60–78, 1991.
[3]  J. M. Fang, P. A. Fowler, C. Sayers, and P. A. Williams, “The chemical modification of a range of starches under aqueous reaction conditions,” Carbohydrate Polymers, vol. 55, no. 3, pp. 283–289, 2004.
[4]  E. Svensson and A.-C. Eliasson, “Crystalline changes in native wheat and potato starches at intermediate water levels during gelatinization,” Carbohydrate Polymers, vol. 26, no. 3, pp. 171–176, 1995.
[5]  A. Rajan, V. S. Prasad, and T. Emilia Abraham, “Enzymatic esterification of starch using recovered coconut oil,” International Journal of Biological Macromolecules, vol. 39, no. 4-5, pp. 265–272, 2006.
[6]  F. Brouillet, G. Baylac, L. Cartilier, and B. Bataille, “High-amylose sodium carboxymethyl starch matrices for oral, sustained drug release: development of a spray-drying manufacturing process,” Drug Development and Industrial Pharmacy, vol. 36, no. 7, pp. 795–805, 2010.
[7]  L. Cartilier, I. Moussa, C. Chebli, and S. Buczkowski, “Substitude amylose as a matrix for sustained drug release,” U.S. Patent 5,879,707, 1999.
[8]  L. Cartilier, M. Ungur, and C. Chebli, “Tablet formulation for sustained drug-release,” Canadian Patent Application 2,491,665, PCT Application no. PCT/CA2005/001934, 2005.
[9]  C. Chebli and L. Cartilier, “Effect of some physical parameters on the sustained drug-release properties of substituted amylose matrices,” International Journal of Pharmaceutics, vol. 193, no. 2, pp. 167–173, 2000.
[10]  S. H. Moghadam, H. W. Wang, E. S. El-Leithy, C. Chebli, and L. Cartilier, “Substituted amylose matrices for oral drug delivery,” Biomedical Materials, vol. 2, no. 1, article S11, pp. S71–S77, 2007.
[11]  C. Chebli, I. Moussa, S. Buczkowski, and L. Cartilier, “Substituted amylose as a matrix for sustained drug release,” Pharmaceutical Research, vol. 16, no. 9, pp. 1436–1440, 1999.
[12]  M. Ungur, N. Yonis, C. Chebli, and L. Cartilier, “The evaluation of carboxymethylamylose for oral drug delivery systems: from laboratory to pilot scale,” in Proceedings of the 3rd International Symposium on Advanced Biomaterials/Biomechanics (ISAB2 '05), vol. 271, Montreal, Canada, 2005.
[13]  S. Edge and R. W. Miller, “Sodium starch glycolate,” in Handbook of Pharmaceutical Excipients, R. C. Rowe, P. J. Sheskey, and S. C. Owen, Eds., pp. 701–704, Pharmaceutical Press, London, UK, 2005.
[14]  V. Lenaerts, I. Moussa, Y. Dumoulin et al., “Cross-linked high amylose starch for controlled release of drugs: recent advances,” Journal of Controlled Release, vol. 53, no. 1–3, pp. 225–234, 1998.
[15]  F. Brouillet, B. Bataille, and L. Cartilier, “High-amylose sodium carboxymethyl starch matrices for oral, sustained drug-release: formulation aspects and in vitro drug-release evaluation,” International Journal of Pharmaceutics, vol. 356, no. 1-2, pp. 52–60, 2008.
[16]  T. Nabais, F. Brouillet, S. Kyriacos et al., “High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 65, no. 3, pp. 371–378, 2007.
[17]  L. J. Scott and C. M. Perry, “Tramadol: a review of its use in perioperative pain,” Drugs, vol. 60, no. 1, pp. 139–176, 2000.
[18]  S. Nossol, M. Schwarzbold, and T. Stadler, “Treatment of pain with sustained-release tramadol 100, 150, 200?mg: a post-marketing surveillance study,” International Journal of Clinical Practice, vol. 52, no. 2, pp. 115–121, 1998.
[19]  S. Grond and A. Sablotzki, “Clinical pharmacology of tramadol,” Clinical Pharmacokinetics, vol. 43, no. 13, pp. 879–923, 2004.
[20]  R. L. Barkin, “Extended-release tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain,” The American Journal of Therapeutics, vol. 15, no. 2, pp. 157–166, 2008.
[21]  P. I. Hair, M. P. Curran, and S. J. Keam, “Tramadol extended-release tablets,” Drugs, vol. 66, no. 15, pp. 2017–2027, 2006.
[22]  H. Malonne, B. Sonet, B. Streel et al., “Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol,” British Journal of Clinical Pharmacology, vol. 57, no. 3, pp. 270–278, 2004.
[23]  M. Raber, H. U. Schulz, M. Schürer, S. Krupp, and H. Momberger, “Pharmacokinetic properties of tramadol sustained release capsules: 3rd communication: investigation of relative bioavailability under steady state conditions,” Arzneimittelforschung, vol. 49, no. 7, pp. 594–598, 1999.
[24]  U.S. Pharmacopeial Convention, The United States Pharmacopeia 36—National Formulary 31, Rockville, Md, USA, 2013.
[25]  M. Walden, F. A. Nicholls, K. J. Smith, and G. T. Tucker, “The effect of ethanol on the release of opioids from oral prolonged-release preparations,” Drug Development and Industrial Pharmacy, vol. 33, no. 10, pp. 1101–1111, 2007.
[26]  T. Dürig and R. Fassihi, “Evaluation of floating and sticking extended release delivery systems: an unconventional dissolution test,” Journal of Controlled Release, vol. 67, no. 1, pp. 37–44, 2000.
[27]  J. W. Moore and H. H. Flanner, “Mathematical comparison of dissolution profiles,” Pharmaceutical Technology, vol. 20, no. 6, pp. 64–74, 1996.
[28]  M. Lemieux, P. Gosselin, and M. A. Mateescu, “Carboxymethyl high amylose starch as excipient for controlled drug release: mechanistic study and the influence of degree of substitution,” International Journal of Pharmaceutics, vol. 382, no. 1-2, pp. 172–182, 2009.
[29]  N. A. Peppas and J. J. Sahlin, “A simple equation for the description of solute release. III. Coupling of diffusion and relaxation,” International Journal of Pharmaceutics, vol. 57, no. 2, pp. 169–172, 1989.
[30]  P. Colombo, R. Bettini, P. Santi, and N. A. Peppas, “Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance,” Pharmaceutical Science and Technology Today, vol. 3, no. 6, pp. 198–204, 2000.
[31]  B. Narasimhan and N. A. Peppas, “Molecular analysis of drug delivery systems controlled by dissolution of the polymer carrier,” Journal of Pharmaceutical Sciences, vol. 86, no. 3, pp. 297–304, 1997.
[32]  V. V. Ranade, “Drug delivery systems 5A. Oral drug delivery,” Journal of Clinical Pharmacology, vol. 31, no. 1, pp. 2–16, 1991.
[33]  M. Lemieux, P. Gosselin, and M. A. Mateescu, “Influence of drying procedure and of low degree of substitution on the structural and drug release properties of carboxymethyl starch,” AAPS PharmSciTech, vol. 11, no. 2, pp. 775–785, 2010.
[34]  C. Calinescu, é. Nadeau, J. Mulhbacher, J. M. Fairbrother, and M.-A. Mateescu, “Carboxymethyl high amylose starch for F4 fimbriae gastro-resistant oral formulation,” International Journal of Pharmaceutics, vol. 343, no. 1-2, pp. 18–25, 2007.
[35]  L. P. Massicotte, W. E. Baille, and M. A. Mateescu, “Carboxylated high amylose starch as pharmaceutical excipients. Structural insights and formulation of pancreatic enzymes,” International Journal of Pharmaceutics, vol. 356, no. 1-2, pp. 212–223, 2008.
[36]  T. D. Reynolds, S. A. Mitchell, and K. M. Balwinski, “Investigation of the effect of tablet surface area/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets,” Drug Development and Industrial Pharmacy, vol. 28, no. 4, pp. 457–466, 2002.
[37]  J. Siepmann, H. Kranz, N. A. Peppas, and R. Bodmeier, “Calculation of the required size and shape of hydroxypropyl methylcellulose matrices to achieve desired drug release profiles,” International Journal of Pharmaceutics, vol. 201, no. 2, pp. 151–164, 2000.
[38]  Y. W. Chien, “Fundamentals of controlled drug administration,” in Novel Drug Delivery System, J. Swarbrick, Ed., pp. 465–574, Marcel Dekker, New York, NY, USA, 1982.
[39]  B. Oshlack, H.-P. Huang, M. Chasin, and P. Goldenheim, “Stabilized sustained release tramadol formulations,” U.S. Patent 6,306,438 B1, 2001.
[40]  W. Helbert and H. Chanzy, “Single crystals of V amylose complexed with n-butanol or n-pentanol: structural features and properties,” International Journal of Biological Macromolecules, vol. 16, no. 4, pp. 207–213, 1994.
[41]  I. Tagarro, J. Herrera, C. Barutell et al., “Effect of a simple dose-escalation schedule on tramadol tolerability: assessment in the clinical setting,” Clinical Drug Investigation, vol. 25, no. 1, pp. 23–31, 2005.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133